Bioxcel TherapeuticsEquity-NMS: BTAI
Equity-NMS: BTAI
$3.1
+0.03
(26 Feb)
Loading Chart
1D
1W
3M
1Y
5Y
Previous close
$3.10
Open
$3.10
Today’s high
$3.15
Today’s low
$2.96
52W low
$1.91
52W high
$32.87
1Y
-89.92%
5Y
-18.42%
PE
-0.44
EPS (TTM)
-7.35
Shares O/S
30.38M
Market cap
94.18M
Insights
BTAI price is below its 200 day moving average
BTAI is in the lowest 10% returns in the past year. It is a low momentum stock. Low momentum stocks tend to underperform in the near term.
In beta. Send feedback here.
Compare with other stock
Price
1D
PE
Market cap
About Bioxcel Therapeutics

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. .


FAQs

Can I buy Bioxcel Therapeutics shares in India?
How to buy Bioxcel Therapeutics shares in India?
What is the share price of Bioxcel Therapeutics?
What is the Market Capitalization of Bioxcel Therapeutics?
What is the PE ratio of Bioxcel Therapeutics?
Is Bioxcel Therapeutics a good stock to buy?
In which sector / industry does Bioxcel Therapeutics operate?